Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Pancreatic Cancer Oncologists in the U.S.

Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
December 8, 2006
Is Rituxan less safe than thought?
Analysis of: Health Canada Issues Health Advisory for Rituxan (www.newsinferno.com)
Symptoms of bowel obstruction include nausea, vomiting, abdominal swelling, abdominal pain, constipation, or diarrhea. Symptoms of gastrointestinal perforation include sudden onset of abdominal pain (worsened by movement), abdominal tenderness, high fever, chills, nausea, and vomiting have been attributed...
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
December 1, 2006
Vaccine therapy for cancer
Analysis of: Pharmexa has started phase II trial in liver cancer with GV1001 (www.pipelinereview.com)
Will the new anti tumor vaccine, GV1001 have a significant impact on hepatocellular cancer (HCC) ?
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 30, 2006
Are we using tamoxifen correctly?
Analysis of: Tamoxifen: Some Women Don't Get Full Benefit (www.cancer.org)
Recent genetic phenotypes have been discovered not to benefit from tamoxifen and how will this effect the market?
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 30, 2006
Hypothyroidism and Sutent
Analysis of: Watch Thyroid While on Sutent (www.cancer.org)
What, if any, impact will the hypothyroidism have on the Sutent market?  
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 27, 2006
Gleevec Warning
Analysis of: Gleevec: New Uses, New Warning (www.cancer.org)
Will recent publications on side effects of Gleevec have an impact on the market of this RX?
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 22, 2006
Herceptin in adjuvant setting
Analysis of: FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy (www.ptcommunity.com)
What impact will the recent approval of Herceptin in the adjuvant setting have on it's use?
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 22, 2006
another epo like product
Analysis of: Roche, Amgen Prepare For Battle (biz.yahoo.com)
What impact would another epo product such as the ROCHE drug, Micera, have on the already competitive market?
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 22, 2006
Do we need another epo agent
Analysis of: C.E.R.A. Corrected Anemia in Chronic Kidney Disease Patients With an Extended Dosing Regimen, Studies Show (www.forbes.com)
There is a new form of erythropoietin intervention in the form of CERA to treat anemia associated with kidney failure associated anemia.
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 21, 2006
Tarceva has yet to peek
Analysis of: NICE rejects use of cancer drug Tarceva (www.pharmaceutical-business-review.com)
Tarceva has recently been rejected by NICE due to the price / benefit ratio determination.
Donald Fleming, MD, Division Head of Hematology and Oncology
Donald Fleming, MD, Division Head of Hematology and Oncology
Davis Health System, Inc.
November 21, 2006
Is Rituxan during and after treatment necessary
Analysis of: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. (www.ncbi.nlm.nih.gov)
Is it beneficial for Rituxan to be given during and after treatment of NHL?

Previous Page : 1 2 3 4 5 6 7 8 9 10 Next81 to 90 of 96

Analytics


Generated at 2009-01-07T19:00:58.307